Business strategy in drug development

Latest Research and Reviews

  • Reviews |

    Drug repurposing — a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication — has the potential for greater success rates and reduced costs compared with developing entirely new drugs. Pirmohamed and colleagues present approaches used for drug repurposing, discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed.

    • Sudeep Pushpakom
    • , Francesco Iorio
    • , Patrick A. Eyers
    • , K. Jane Escott
    • , Shirley Hopper
    • , Andrew Wells
    • , Andrew Doig
    • , Tim Guilliams
    • , Joanna Latimer
    • , Christine McNamee
    • , Alan Norris
    • , Philippe Sanseau
    • , David Cavalla
    •  & Munir Pirmohamed
  • Reviews |

    In 2011, AstraZeneca set out to improve its research and development (R&D) productivity by focusing decision-making using a framework with five technical determinants: the right target, right tissue, right safety, right patient and right commercial potential. Here, Pangalos and colleagues describe the progress made using this '5R framework', with metrics indicating improved success rates, and discuss where the approach has failed and the lessons learned.

    • Paul Morgan
    • , Dean G. Brown
    • , Simon Lennard
    • , Mark J. Anderton
    • , J. Carl Barrett
    • , Ulf Eriksson
    • , Mark Fidock
    • , Bengt Hamrén
    • , Anthony Johnson
    • , Ruth E. March
    • , James Matcham
    • , Jerome Mettetal
    • , David J. Nicholls
    • , Stefan Platz
    • , Steve Rees
    • , Michael A. Snowden
    •  & Menelas N. Pangalos
  • Research |

    Shih and colleagues analyse comprehensive industry-wide data on drug development projects pursued during the past 20 years, classified according to the mechanism and indication for each project. Their findings indicate several points and trends that may be useful in understanding and improving the productivity of the pharmaceutical industry, including areas with substantial success or failure and the relative extent of novelty in completed and ongoing projects.

    • Hsin-Pei Shih
    • , Xiaodan Zhang
    •  & Alex M. Aronov
  • Reviews |

    The costs of both newly approved, and established anticancer drugs have risen dramatically in the past decade, to the point where the costs of such treatments are becoming unsustainable. In this perspective, the authors outline the extent of this problem, and how it is likely to continue, while also suggesting measures that could be taken in future to address these rising costs.

    • Vinay Prasad
    • , Kevin De Jesús
    •  & Sham Mailankody

News and Comment